Source comparison
Comparison Table: PT-141 vs Established Therapies
PT-141 (bremelanotide) MC4R/MC3R agonist (central neural pathway activation) Intranasal spray 2.7 hours HSDD in premenopausal women First centrally-acting FDA-approved option for female sexual dysfunction. Targets desire circuits in the brain rather than vascu
This comparison does not assign a generated winner or score.
- PT-141 (bremelanotide)
- MC4R/MC3R agonist (central neural pathway activation)
- Intranasal spray
- 2.7 hours
- HSDD in premenopausal women
- First centrally-acting FDA-approved option for female sexual dysfunction. Targets desire circuits in the brain rather than vascular response
- Sildenafil (Viagra)
- PDE5 inhibitor (peripheral vasodilation)
- Oral tablet
- 3–5 hours
- Erectile dysfunction
- Effective for vascular-mediated arousal disorders, no direct effect on central desire pathways
- Flibanserin (Addyi)
- Serotonin 5-HT1A agonist / 5-HT2A antagonist
- Oral tablet (daily)
- 11 hours
- Daily dosing required, drug-drug interactions with alcohol and CYP3A4 inhibitors limit use
- Testosterone replacement (systemic)
- Androgen receptor agonist (hormonal)
- Transdermal patch/gel, injection
- Varies (days to weeks)
- Female sexual dysfunction (off-label)
- Hormonal approach, efficacy in postmenopausal women only, virilisation risk with supraphysiologic doses